Merck & Co. and Moderna Inc. said Wednesday that an experimental mRNA vaccine reduced melanoma recurrence rates by about 49% [1].
The results represent a potential shift in how doctors treat high-risk skin cancer patients. By targeting the specific mechanisms of the disease, the vaccine aims to prevent the cancer from returning after initial treatment.
Data released this week indicates the vaccine extended the time before cancer returned in high-risk patients [2]. The 49% reduction in recurrence was measured over a five-year period [1]. This approach utilizes mRNA technology to prime the immune system to recognize and attack remaining cancer cells.
Market reactions to the clinical data were immediate. Moderna stock rose 90% following the announcement [3]. The partnership between the two pharmaceutical giants focuses on the development of personalized cancer therapies, a field that has seen increased investment since the success of mRNA COVID-19 vaccines.
While the initial late-stage data is promising, the companies continue to monitor the long-term efficacy of the treatment [3]. The trial specifically targeted patients who were considered high-risk for recurrence, meaning the results may not apply to all melanoma patients.
Merck and Moderna said the vaccine shows promise in delaying the return of the disease [2]. The companies are working to further validate these findings as they move toward potential regulatory approval.
“Experimental mRNA vaccine reduced melanoma recurrence rates by about 49%”
The success of this trial suggests that mRNA technology can be effectively pivoted from infectious diseases to oncology. If these results hold, the vaccine could move melanoma treatment from a reactive model to a preventative one for high-risk survivors, potentially reducing the need for more invasive secondary treatments.
